Dunad Therapeutics
Pearl Huang is the CEO and President of Dunad Therapeutics. Previously, Pearl served as the CEO of Cygnal Therapeutics and held various executive positions at Roche, GlaxoSmithKline, Beigene Bio, Merck and Co, GSK, and DuPont Pharmaceuticals Company. Pearl's expertise lies in drug discovery, oncology, molecular biology, and portfolio management. Pearl holds a Ph.D. in Molecular Biology from Massachusetts Institute of Technology and a SB in Life Sciences from Princeton University.
This person is not in any offices
Dunad Therapeutics
1 followers
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted oral protein degradation therapies. Dunad’s platform enables selective degradation via direct target modification using tunable mono-valent small molecules, allowing for the development of more drug-like, orally bioavailable and CNS-accessible protein degraders.
Employees
11-50